Shengen Xiong is a cancer drug discovery scientist specializing in oncology research and immunotherapy development. His work focuses on the discovery and advancement of novel therapeutic strategies for cancer, with particular expertise in antibody engineering and T-cell redirection technologies, including T-cell engagers (TCEs) and chimeric antigen receptor (CAR) T-cell therapies. His current research is focused on the development of T-cell engager immunotherapies for patients with calreticulin (CALR)-mutated myeloproliferative neoplasms (MPNs). By integrating cancer biology, target discovery, and therapeutic development, Shengen aims to translate scientific insights into innovative treatments that address unmet medical needs. His long-term goal is to advance oncology drug discovery and contribute to the development of next-generation cancer therapies that improve outcomes for patients with cancer.